Hemenway Trust Co LLC increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,235 shares of the biopharmaceutical company’s stock after buying an additional 986 shares during the period. Hemenway Trust Co LLC’s holdings in Gilead Sciences were worth $2,352,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in GILD. Bridges Investment Counsel Inc. boosted its stake in Gilead Sciences by 58.2% in the first quarter. Bridges Investment Counsel Inc. now owns 18,689 shares of the biopharmaceutical company’s stock worth $1,269,000 after buying an additional 6,875 shares during the period. Bridges Investment Management Inc. boosted its stake in Gilead Sciences by 65.6% in the first quarter. Bridges Investment Management Inc. now owns 59,150 shares of the biopharmaceutical company’s stock worth $4,018,000 after buying an additional 23,439 shares during the period. F&V Capital Management LLC boosted its stake in Gilead Sciences by 3.1% in the first quarter. F&V Capital Management LLC now owns 79,450 shares of the biopharmaceutical company’s stock worth $5,396,000 after buying an additional 2,425 shares during the period. Triangle Securities Wealth Management boosted its stake in Gilead Sciences by 30.5% in the first quarter. Triangle Securities Wealth Management now owns 3,832 shares of the biopharmaceutical company’s stock worth $260,000 after buying an additional 895 shares during the period. Finally, Private Asset Management Inc. boosted its stake in Gilead Sciences by 4.1% in the first quarter. Private Asset Management Inc. now owns 115,410 shares of the biopharmaceutical company’s stock worth $7,839,000 after buying an additional 4,582 shares during the period. 74.02% of the stock is currently owned by institutional investors.

Gilead Sciences, Inc. (NASDAQ:GILD) traded down 1.12% during trading on Thursday, hitting $72.53. 3,045,550 shares of the company’s stock traded hands. The stock has a market cap of $94.72 billion, a P/E ratio of 7.88 and a beta of 1.21. The firm’s 50-day moving average price is $72.56 and its 200 day moving average price is $68.80. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $82.10.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. During the same quarter in the prior year, the business earned $3.08 earnings per share. The business’s quarterly revenue was down 8.2% compared to the same quarter last year. Analysts anticipate that Gilead Sciences, Inc. will post $8.76 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.84%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s payout ratio is currently 22.58%.

WARNING: “Hemenway Trust Co LLC Has $2.35 Million Stake in Gilead Sciences, Inc. (GILD)” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/17/hemenway-trust-co-llc-has-2-35-million-stake-in-gilead-sciences-inc-gild.html.

GILD has been the topic of a number of analyst reports. Gabelli restated a “buy” rating and set a $85.00 target price on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Stifel Nicolaus restated a “buy” rating and set a $87.00 target price on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 target price on the stock in a research report on Tuesday, May 2nd. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.88 target price on the stock. in a research report on Tuesday, April 25th. Finally, Piper Jaffray Companies restated a “buy” rating on shares of Gilead Sciences in a research report on Friday, April 21st. Twelve analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $80.31.

In related news, EVP Gregg H. Alton sold 40,000 shares of the firm’s stock in a transaction on Friday, July 21st. The shares were sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the completion of the sale, the executive vice president now directly owns 137,488 shares of the company’s stock, valued at approximately $10,174,112. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The disclosure for this sale can be found here. Insiders sold 206,666 shares of company stock valued at $15,223,184 in the last three months. Company insiders own 1.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.